Brain Cancer | Specialty

Dr. Yael Cohen on Anti-Angiogenic Agent VB-111

October 29th 2015

Yael Cohen, MD, vice president of Clinical Development at VBL Therapeutics Pharmaceuticals, discusses VB-111, a highly targeted anti-angiogenic agent that is being investigated in several tumor types.

Three FDA Approvals and Two Priority Reviews

October 9th 2015

FDA Expands Optune's Glioblastoma Multiforme Indication

October 5th 2015

The FDA has approved Optune in combination with adjuvant temozolomide as a treatment for patients with newly diagnosed glioblastoma multiforme following surgery, chemotherapy, and radiation therapy.

Dr. Piccioni on Tumor Profiles of Brain Metastases

September 2nd 2015

David Piccioni, MD, PhD, assistant professor, Neuroscience and Neuro-Oncology, UC San Diego Health, discusses tumor profiling of brain metastases of patients with non-small cell lung cancer, breast cancer, and melanoma.

Blocking the PD-1/PD-L1 Signaling Pathway in Malignant Glioma: Current and Future Perspectives

August 9th 2015

Blockade of the PD-1/PD-L1 pathway is a novel and attractive treatment approach to many cancers, including malignant glioma, because of its potential to restore anti-tumor immunity.

Lenalidomide Highly Effective in Early Phase CNS Lymphoma Study

June 20th 2015

Lenalidomide in combination with rituximab and as maintenance monotherapy is highly active in patients with relapsed/refractory central nervous system non-Hodgkin lymphoma.

Dr. Michalski on Minimizing Long-Term Consequences of Radiation

May 5th 2015

Jeff Michalski, MD, professor, vice chair of Radiation Oncology, Washington University School of Medicine, Siteman Cancer Center explains the importance of minimizing the long-term consequences of radiation.

Dr. Daniel Brat on Characterizing Diffuse Lower Grade Gliomas

April 27th 2015

Daniel J. Brat, MD, PhD, vice chair, Translational Programs, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, director, Cancer Tissue and Pathology Shared Resource, Winship Cancer Institute, discusses genomic characterization of diffuse lower grade gliomas.

Liposomal Encapsulation of Radiotherapeutics Holds Promise in Treating Glioblastoma

April 8th 2015

Andrew Brenner, MD, PhD, discusses how liposomal encapsulation of radiotherapeutics holds significant promise as a treatment of glioblastoma.

Dr. Battiste on Biomarkers in Glioblastoma

March 19th 2015

James Battiste, MD, PhD, assistant professor at the University of Oklahoma department of neurology and researcher at Stephenson Cancer Center, discusses research in glioblastoma (GBM).

FDA Approvals, Breakthrough Designations, Priority Reviews, and More

February 27th 2015

FDA Grants Rindopepimut Breakthrough Designation for EGFRvIII-Positive Glioblastoma

February 23rd 2015

Rindopepimut (Rintega) has gained a Breakthrough Therapy Designation from the FDA to treat adult patients with glioblastoma multiforme that test positive for the epidermal growth factor receptor variant.

Pre-Chemo Abiraterone Extends Survival in CRPC

November 21st 2014

ADT With GnRH Antagonists in Prostate Cancer

November 21st 2014

Upcoming Advances for GU Cancers

November 21st 2014

Latest News & Insight: November 20, 2014

November 21st 2014

Experts Discuss Immunotherapy's Potential in Neuro-Oncology

November 17th 2014

Immunotherapy's promise as well as its challenges as a treatment for patients with brain cancer was the focus of a plenary session held November 15 at the Society of Neuro-Oncology's (SNO) 2014 Annual Meeting in Miami Beach.

Oncolytic Virus Shows Early Promise in Glioma

November 17th 2014

The oncolytic virus Delta-24-RGD can infect, replicate, and kill glioma cells in patients, according to phase I research presented at the 2014 Society for Neuro-Oncology (SNO) Annual Meeting in Miami.

Dr. de Groot Discusses Altiratinib as Potential Treatment for Glioblastoma

November 17th 2014

John F de Groot, MD, nuro-oncologist, MD Anderson Cancer Center, discusses the efficacy of the novel c-MET inhibitor altiratinib in glioblastoma.

Dr. Stupp Discusses NovoTTF With Temozolomide in Glioblastoma

November 16th 2014

Roger Stupp, MD, Professor of Oncology, University of Zürich; Chairman, Department of Oncology and Cancer Center, University of Zürich Hospital, Zürich, Switzerland, discusses the interim analysis of the EF-14 trial, which compared NovoTTF-100A together with temozolomide versus temozolomide alone in patients with newly diagnosed glioblastoma multiforme (GBM).